A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
A phase 3 trial testing GR1803 in multiple myeloma, now recruiting.
Overview
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT07452198, led by Genrix (Shanghai) Biopharmaceutical, and recruiting when checked on 2026-09-11. Official title: A Phase 3, Multicenter, Open-Label, Randomised Study Comparing GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy Including Lenalidomide and Proteasome Inhibitors. Planned enrolment is 358 participants (estimated). The study started in 2026-03-09 and primary completion is expected in 2029-03. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag ctgov-ingest.
- TrialA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Shares Multiple myeloma and the tag ctgov-ingest.
- TrialA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag ctgov-ingest.
- TrialA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag ctgov-ingest.
- TrialCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Shares Multiple myeloma and the tag ctgov-ingest.
- TrialA Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag ctgov-ingest.
- TrialA Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Shares Multiple myeloma and the tag ctgov-ingest.
- TrialA Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
Shares Multiple myeloma and the tag ctgov-ingest.